WTA
KYTX icon

Washington Trust Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Washington Trust Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60
Closed -$294 – 689
2024
Q3 		$294 Hold
60
– – ﹤0.01% 658
2024
Q2 		$450 Hold
60
– – ﹤0.01% 656
2024
Q1 		$1.49K Buy
+60
New +$1.67K ﹤0.01% 647

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Washington Trust Advisors's KYTX Position: Q4 2024 in Review

Washington Trust Advisors sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 60 shares — an estimated $294 sold.

Washington Trust Advisors first reported a position in KYTX in Q1 2024 and held it in 3 quarters. The position peaked at $1.49K in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Washington Trust Advisors reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Washington Trust Advisors sold 60 Kyverna Therapeutics shares in Q4 2024, an estimated $294.
  • Washington Trust Advisors first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 3 quarters.
  • Washington Trust Advisors's Kyverna Therapeutics position peaked at $1.49K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Washington Trust Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.